Đang chuẩn bị liên kết để tải về tài liệu:
Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by Nacetylcysteine

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

The metabolic inhibitor 3-bromopyruvate (3-BrPA) is a promising anti-cancer alkylating agent, shown to inhibit growth of some colorectal carcinoma with KRAS mutation. Recently, we demonstrated increased resistance to 3-BrPA in wt p53 tumor cells compared to those with p53 silencing or mutation. |

TÀI LIỆU LIÊN QUAN

MicroRNA response to hypoxic stress in soft tissue sarcoma cells: MicroRNA mediated regulation of HIF3α

Circulatory collapse during wound closure in spine surgery with an unknown cause: A possible adverse effect of topical application of vancomycin?

Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells

Báo cáo khoa học: Hypoxic resistance to articular chondrocyte apoptosis – a possible mechanism of maintaining homeostasis of normal articular cartilage

Effects of hypoxia on human cancer cell line chemosensitivity

Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by Nacetylcysteine